AustraliaHealth

Aroa Biosurgery (ASX:ARX) has achieved a clinical milestone following the completion of its randomised controlled trial for Symphony.

Reece (ASX:REH) announced a comprehensive redesign of its remuneration framework for top-tier leadership.

Lumos Diagnostics (ASX:LDX) announced a US market expansion triggered by the US FDA granting a CLIA waiver for its flagship point-of-care test, FebriDx.

4DMedical (ASX:4DX) secured CE Mark clearance for its pioneering CT:VQ software.

Radiopharm Theranostics (ASX:RAD) has dosed the first patient in its Phase 1 clinical trial of RAD 402.

Firebrick Pharma (ASX:FRE) has secured its first-ever regulatory approval for Nasodine nasal spray.

Monash IVF Group (ASX:MVF) has appointed Birol Akdogan as its Interim CFO, effective March 26.

Clarity Pharmaceuticals (ASX:CU6) has entered into a large-scale manufacturing supply agreement with Theragenics for the production of copper-64.

Melbourne-based 4DMedical (ASX:4DX) announced the deployment of its CT:VQ technology at the Mayo Clinic.

Recce Pharmaceuticals (ASX:RCE) has been granted a Family 4 patent for its proprietary synthetic anti-infectives.

Echo IQ (ASX: EIQ) announced an expanded agreement to distribute its AI-driven heart failure solution, EchoSolv HF.

Cyclopharm (ASX:CYC) announced a new multi-site agreement with Northwestern Memorial HealthCare, a premier academic health system based in Chicago.